{"gene":"TNFRSF10D","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1997,"finding":"TRAIL-R4 (TNFRSF10D) was cloned and characterized as a receptor that binds TRAIL, activates NF-κB similarly to TRAIL-R1/R2, but cannot induce apoptosis due to its incomplete/truncated death domain. Transient overexpression of TRAIL-R4 in TRAIL-sensitive cells confers complete protection against TRAIL-mediated killing, establishing its function as a decoy receptor that inhibits TRAIL cytotoxicity.","method":"Molecular cloning, NF-κB activation assay, transient overexpression with cell death assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 — original cloning paper with multiple functional assays; replicated by independent lab (PMID:9537512)","pmids":["9430226"],"is_preprint":false},{"year":1998,"finding":"TRUNDD (TRAIL-R4/TNFRSF10D) has an extracellular TRAIL-binding domain but lacks a functional intracellular death domain; ectopic expression of TRUNDD attenuates TRAIL-induced apoptosis in mammalian cells, confirming its role as an inhibitory decoy receptor.","method":"Molecular cloning, transient overexpression, cell death assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — independent replication of decoy function with direct overexpression/apoptosis assay","pmids":["9537512"],"is_preprint":false},{"year":2000,"finding":"TRUNDD (DcR2/TRAIL-R4) expression is induced by p53 (via adenovirus-p53 overexpression), and overexpression of TRUNDD delays killing by TRAIL, p53, or KILLER/DR5. Protection against TRAIL did not require an intact intracellular domain (ICD), but the first 43 amino acids of the ICD were required for protection against p53- or KILLER/DR5-induced cell death, revealing distinct structural requirements for different protective functions.","method":"Adenoviral p53 overexpression, TRUNDD overexpression, deletion mutagenesis, co-transfection cell death assay","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis dissecting ICD requirements combined with functional cell death assays","pmids":["10933923"],"is_preprint":false},{"year":2005,"finding":"DcR2 (TNFRSF10D) is a direct p53 target gene: a p53-binding site (p53BS) was identified in the first intron of DcR2, p53 protein binds to this site in intact cells (chromatin immunoprecipitation), and the p53BS is sufficient to drive transcriptional activation by wild-type p53. Overexpression of DcR2 conferred resistance to TRAIL-mediated apoptosis and attenuated chemotherapeutic agent-induced apoptosis, while DcR2 silencing enhanced chemotherapy-induced apoptosis.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with p53BS, siRNA knockdown, cell death assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP plus reporter assay plus mutagenesis of binding site plus functional KD/OE","pmids":["16230375"],"is_preprint":false},{"year":2011,"finding":"Upon TRAIL binding, TRAIL-R4 forms a heteromeric complex with the agonistic receptor TRAIL-R2, leading to reduced caspase-8 activation and apoptosis. Additionally, in a ligand-independent manner, TRAIL-R4 signals through AKT/PI3K in HeLa cells, inducing morphological changes, enhanced proliferation in vitro, and tumor growth in vivo; disruption of PI3K/AKT with LY294002, p85 siRNA, or PTEN overexpression partially restored TRAIL-mediated apoptosis.","method":"Ectopic TRAIL-R4 expression, caspase-8 activation assay, PI3K/AKT inhibition (LY294002, siRNA, PTEN overexpression), in vivo xenograft tumor growth assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (pharmacological, genetic, in vivo) with functional readouts; establishes heteromeric complex and AKT signaling","pmids":["21625476"],"is_preprint":false},{"year":2003,"finding":"Acquisition of DcR2 (TRAIL-R4) surface expression by BTK-143 osteosarcoma cells during serial passaging correlates with progressive resistance to TRAIL-induced apoptosis; blocking DcR2 function with a specific anti-DcR2 antibody restored TRAIL sensitivity in a dose-dependent manner, directly implicating DcR2 surface expression in TRAIL resistance.","method":"Flow cytometry, anti-DcR2 antibody blocking, apoptosis assay","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blocking with dose-dependent restoration of apoptosis; single lab","pmids":["12838325"],"is_preprint":false},{"year":2005,"finding":"IFNγ and IFNα strongly inhibit TRAIL-R4 cell surface expression through proteasome-dependent proteolytic degradation (blocked by MG132 and a protease inhibitor cocktail), while having moderate or inducing effects on TRAIL-R2. siRNA-mediated inhibition of TRAIL-R4 expression sensitizes cells to TRAIL- but not CD95L-induced apoptosis.","method":"Flow cytometry, proteasome inhibitor (MG132), protease inhibitor cocktail, siRNA knockdown, apoptosis assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection with proteasome inhibitors and siRNA; single lab","pmids":["16185657"],"is_preprint":false},{"year":2006,"finding":"Testosterone specifically controls DcR2 (TNFRSF10D) expression in the adult rat ventral prostate. Androgen deprivation (castration) reduces DcR2 mRNA and protein levels, and testosterone replacement prevents this decrease; the anti-androgen flutamide also specifically decreases DcR2 expression. No changes in DR4, DR5, DcR1, or TRAIL were observed, establishing DcR2 as an androgen-regulated gene in prostate.","method":"Castration model, testosterone replacement, flutamide treatment, RT-PCR, Western blot","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — orthogonal in vivo experiments (castration + hormone replacement + antagonist) with mRNA and protein readouts; single lab","pmids":["16245307"],"is_preprint":false},{"year":2014,"finding":"PARP13 (ZAP/ZC3HAV1) binds to the 3' UTR of TRAILR4 (TNFRSF10D) mRNA and destabilizes it in an exosome-dependent manner, post-transcriptionally repressing TRAILR4 expression. Knockdown of PARP13 leads to upregulation of TRAILR4 transcript and reduced cell sensitivity to TRAIL-mediated apoptosis, establishing PARP13 as a regulator of the cellular TRAIL response via TRAILR4 mRNA decay.","method":"PARP13 knockdown (siRNA), RNA-seq, RNA immunoprecipitation, exosome-dependent mRNA decay assay, TRAIL apoptosis assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (RIP, exosome inhibition, KD with functional readout) in single rigorous study","pmids":["25382312"],"is_preprint":false},{"year":2022,"finding":"Stable knockdown of endogenous TRAIL-R4 in Colo357 and MDA-MB-231 cancer cells reveals context-dependent signaling: in Colo357 cells, TRAIL-R4 KD strongly increased apoptosis and reduced clonogenic survival; in MDA-MB-231 cells, TRAIL-R4 KD paradoxically inhibited cell death and improved survival by upregulating Bcl-xL (Navitoclax restored apoptosis). TRAIL-R4 KD also reduced FLIPs, XIAP, and cIAP2 levels in MDA-MB-231. In both lines, TRAIL-R4 KD constitutively increased AKT and ERK activity, and potentiated TRAIL-induced NF-κB and MAPK signaling.","method":"Stable shRNA knockdown, clonogenic survival assay, Western blot (caspase-8, FLIPs, XIAP, cIAP2, Bcl-xL), Navitoclax inhibition, AKT/ERK/p38/NF-κB pathway activation assays","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 — stable KD with multiple pathway readouts and rescue experiment (Navitoclax); mechanistically rigorous","pmids":["36158196"],"is_preprint":false},{"year":2025,"finding":"DcR2 (TNFRSF10D) has greater binding affinity for DR5 than for TRAIL itself. DcR2 forms a heterocomplex with DR5 through its PLAD (pre-ligand assembly domain), and deletion of PLAD eliminates the cardioprotective effect of an hDcR2-Fc fusion protein in a mouse model of myocardial ischemia/reperfusion injury. This establishes DcR2 as a ligand for DR5 that blocks apoptosis by DR5 heterocomplex formation via PLAD, independent of TRAIL binding.","method":"Affinity binding assay (DcR2 vs. TRAIL and DR5), PLAD deletion mutagenesis, hDcR2-Fc fusion protein, mouse myocardial I/R injury model, apoptosis assay","journal":"International journal of biological macromolecules","confidence":"High","confidence_rationale":"Tier 1-2 — affinity assay plus domain mutagenesis plus in vivo functional model; multiple orthogonal methods","pmids":["40154678"],"is_preprint":false},{"year":2024,"finding":"The transcription factor ELF3 regulates TRAIL sensitivity in breast cancer cells by modulating DcR2 (TNFRSF10D) expression; ELF3 overexpression in MDA-MB-231 and MCF7 cells reverses TRAIL resistance and simultaneously downregulates DcR2 protein levels.","method":"ELF3 overexpression, cell viability assay, cleaved caspase-3 immunoblotting, DcR2 immunoblotting","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 3 — overexpression with functional readout linking ELF3→DcR2→TRAIL sensitivity; single lab, no ChIP or direct promoter assay","pmids":["38787503"],"is_preprint":false},{"year":2002,"finding":"Tumor-specific down-regulation of DcR2 (TNFRSF10D) in neuroblastoma and other tumor cell lines is associated with dense CpG island hypermethylation of the DcR2 promoter; treatment with the demethylating agent 5-aza-2'-deoxycytidine results in partial demethylation and restored DcR2 mRNA expression, establishing epigenetic silencing as a mechanism of DcR2 loss.","method":"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine demethylation, RT-PCR","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological demethylation restores expression; single lab but orthogonal methylation and expression methods","pmids":["11929838"],"is_preprint":false}],"current_model":"TNFRSF10D (TRAIL-R4/DcR2) is a decoy receptor that binds TRAIL but cannot induce apoptosis due to its truncated death domain; it inhibits TRAIL-induced apoptosis by competing with death receptors and by forming heteromeric complexes with TRAIL-R2/DR5 via its PLAD domain, while also activating NF-κB and PI3K/AKT pro-survival signaling; its expression is transcriptionally regulated by p53 and androgens, post-transcriptionally repressed by PARP13-mediated mRNA decay, and epigenetically silenced by promoter hypermethylation in tumors, with interferon-induced proteasomal degradation providing an additional layer of regulation."},"narrative":{"teleology":[{"year":1997,"claim":"The cloning of TRAIL-R4/DcR2 resolved how cells could bind TRAIL yet resist apoptosis, revealing a receptor that activates NF-κB but has a truncated death domain incapable of death signaling, thereby establishing the concept of a decoy receptor in the TRAIL system.","evidence":"Molecular cloning, NF-κB reporter assays, and transient overexpression protection against TRAIL-mediated killing; independently replicated","pmids":["9430226","9537512"],"confidence":"High","gaps":["Mechanism by which DcR2 blocks signaling at death receptors was unknown beyond simple competition for ligand","Physiological expression patterns and transcriptional regulation uncharacterized","Whether DcR2 transmits any active survival signals beyond NF-κB was unknown"]},{"year":2000,"claim":"Deletion mutagenesis of DcR2's intracellular domain distinguished two protective mechanisms: the extracellular domain sufficed to block TRAIL, but the first 43 amino acids of the ICD were specifically required for protection against p53- or KILLER/DR5-induced cell death, revealing that DcR2 is not simply a passive ligand sink.","evidence":"ICD deletion constructs co-expressed with p53 or KILLER/DR5, functional cell death assays","pmids":["10933923"],"confidence":"High","gaps":["The signaling mechanism mediated by the proximal ICD fragment was not identified","Whether DcR2 physically interacts with DR5 was not tested"]},{"year":2002,"claim":"The finding that DcR2 promoter hypermethylation silences its expression in neuroblastoma and other tumors, reversible by demethylating agents, explained how tumors can lose a decoy receptor and provided an epigenetic mechanism for altered TRAIL pathway sensitivity in cancer.","evidence":"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment restoring mRNA","pmids":["11929838"],"confidence":"Medium","gaps":["Functional consequences of demethylation on TRAIL-induced apoptosis were not directly tested","Single-lab observation at this time; breadth across tumor types was limited"]},{"year":2003,"claim":"Anti-DcR2 antibody blocking in osteosarcoma cells that had acquired DcR2 surface expression during passaging restored TRAIL sensitivity dose-dependently, providing the first loss-of-function evidence that endogenous DcR2 at the cell surface is a physiologically relevant barrier to TRAIL-induced apoptosis.","evidence":"Flow cytometry for DcR2 surface expression, anti-DcR2 blocking antibody, apoptosis assays","pmids":["12838325"],"confidence":"Medium","gaps":["Mechanism of DcR2 upregulation during passaging was not determined","Antibody blocking does not distinguish competition for TRAIL from disruption of receptor–receptor complexes"]},{"year":2005,"claim":"Identification of a direct p53-binding site in DcR2's first intron by ChIP and reporter assays established DcR2 as a bona fide p53 target gene, revealing a negative feedback loop in which p53-induced apoptosis is modulated by p53-driven expression of an anti-apoptotic decoy receptor.","evidence":"ChIP, luciferase reporter with p53BS, p53BS mutagenesis, siRNA knockdown with chemotherapy apoptosis assay","pmids":["16230375"],"confidence":"High","gaps":["Whether p53-mediated DcR2 induction occurs in non-tumor physiological contexts was not shown","Relative contribution of p53-driven DcR2 vs. other p53 targets in modulating apoptotic outcome was unclear"]},{"year":2005,"claim":"Demonstrating that interferons (IFNγ, IFNα) reduce DcR2 surface expression via proteasome-dependent degradation revealed a protein-level regulatory mechanism that sensitizes cells to TRAIL, complementing the known transcriptional and epigenetic controls.","evidence":"Flow cytometry, proteasome inhibitor MG132 rescue, siRNA-mediated DcR2 knockdown, TRAIL apoptosis assay","pmids":["16185657"],"confidence":"Medium","gaps":["The E3 ubiquitin ligase responsible for DcR2 ubiquitylation was not identified","Whether interferon-induced degradation operates in vivo was not tested"]},{"year":2006,"claim":"The finding that testosterone specifically maintains DcR2 expression in rat prostate (while other TRAIL receptors are unaffected) identified DcR2 as an androgen-regulated gene, providing a mechanism by which androgen deprivation therapy could sensitize prostate tissue to TRAIL-mediated apoptosis.","evidence":"Castration, testosterone replacement, flutamide treatment; RT-PCR and Western blot in rat ventral prostate","pmids":["16245307"],"confidence":"Medium","gaps":["Whether androgen receptor directly binds the DcR2 promoter was not tested","Functional link between androgen-regulated DcR2 and TRAIL sensitivity in prostate was not demonstrated"]},{"year":2011,"claim":"The discovery that TRAIL-R4 forms a heteromeric complex with TRAIL-R2 to reduce caspase-8 activation, and independently activates AKT/PI3K signaling to promote proliferation and tumor growth, established DcR2 as both a dominant-negative receptor and an active oncogenic signaling molecule.","evidence":"Ectopic TRAIL-R4 expression, caspase-8 assay, PI3K inhibition (LY294002, p85 siRNA, PTEN OE), xenograft model","pmids":["21625476"],"confidence":"High","gaps":["The molecular mechanism linking DcR2's truncated death domain to PI3K/AKT activation was not resolved","The stoichiometry and structural basis of the TRAIL-R4/TRAIL-R2 heterocomplex were not determined"]},{"year":2014,"claim":"Identification of PARP13 as a post-transcriptional repressor that binds the TRAILR4 3′ UTR and triggers exosome-dependent mRNA decay added an RNA regulatory layer to DcR2 control, explaining how cells can fine-tune TRAIL sensitivity independently of transcription.","evidence":"PARP13 siRNA knockdown, RNA-seq, RNA immunoprecipitation, exosome inhibition, TRAIL apoptosis assay","pmids":["25382312"],"confidence":"High","gaps":["Specific RNA sequences/structures in the 3′ UTR recognized by PARP13 were not mapped","Whether PARP13-mediated DcR2 repression operates in non-cancer contexts was not explored"]},{"year":2022,"claim":"Stable DcR2 knockdown in two cancer cell lines revealed that DcR2's role is context-dependent: pro-survival in one line (Colo357) but paradoxically pro-apoptotic in another (MDA-MB-231) via compensatory Bcl-xL upregulation, challenging a simple decoy receptor model and showing that DcR2 actively shapes the signaling landscape through NF-κB, AKT, and ERK pathways.","evidence":"Stable shRNA KD in Colo357 and MDA-MB-231, clonogenic assays, pathway Western blots, Navitoclax rescue of Bcl-xL-dependent survival","pmids":["36158196"],"confidence":"High","gaps":["Mechanism by which DcR2 loss leads to Bcl-xL upregulation in MDA-MB-231 was not delineated","Which downstream effectors mediate the context-dependent switch was not resolved"]},{"year":2025,"claim":"Demonstrating that DcR2 binds DR5 with higher affinity than TRAIL and that its PLAD domain is required for heterocomplex formation and cardioprotection in myocardial ischemia/reperfusion injury redefined DcR2 as a direct DR5 ligand/modulator acting through receptor–receptor interactions rather than solely through ligand sequestration.","evidence":"Affinity binding assays, PLAD deletion mutagenesis, hDcR2-Fc fusion protein, mouse myocardial I/R model","pmids":["40154678"],"confidence":"High","gaps":["Structural basis of the PLAD-mediated DcR2–DR5 interaction at atomic resolution is unknown","Whether PLAD-dependent DR5 inhibition operates in tissues beyond the heart was not tested","Relative contribution of TRAIL sequestration vs. DR5 heterocomplexing in physiological settings remains unquantified"]},{"year":null,"claim":"Key open questions include the structural basis of DcR2–DR5 PLAD interaction, the signaling intermediates linking DcR2's truncated death domain to PI3K/AKT activation, and the molecular determinants that dictate context-dependent pro-survival versus pro-apoptotic outcomes upon DcR2 loss.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of the DcR2–DR5 heterocomplex exists","The adaptor proteins linking DcR2 to PI3K/AKT have not been identified","In vivo genetic knockout models for DcR2 have not been reported"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,4,10]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,5,6]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,2,3,4,5,9,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,9]}],"complexes":[],"partners":["TNFSF10","TNFRSF10B","ZC3HAV1","TP53"],"other_free_text":[]},"mechanistic_narrative":"TNFRSF10D (TRAIL-R4/DcR2) is a decoy receptor in the TRAIL death receptor pathway that antagonizes apoptosis through multiple mechanisms while simultaneously activating pro-survival signaling. It binds TRAIL via its extracellular domain but cannot transduce apoptotic signals due to a truncated intracellular death domain; instead, it inhibits apoptosis by competing with death receptors for TRAIL and by forming heteromeric complexes with TRAIL-R2/DR5 through its pre-ligand assembly domain (PLAD), with DcR2 exhibiting greater binding affinity for DR5 than for TRAIL itself [PMID:9430226, PMID:40154678]. In a ligand-independent manner, TNFRSF10D activates NF-κB, AKT/PI3K, and ERK signaling to promote cell survival and proliferation, though stable knockdown reveals context-dependent effects whereby loss of DcR2 can paradoxically inhibit apoptosis in certain cell lines through compensatory Bcl-xL upregulation [PMID:21625476, PMID:36158196]. Its expression is transcriptionally controlled by p53 (via an intronic p53-binding site) and androgens, post-transcriptionally repressed by PARP13-mediated mRNA decay, epigenetically silenced by promoter CpG hypermethylation in tumors, and regulated at the protein level by interferon-induced proteasomal degradation [PMID:16230375, PMID:16245307, PMID:25382312, PMID:11929838, PMID:16185657]."},"prefetch_data":{"uniprot":{"accession":"Q9UBN6","full_name":"Tumor necrosis factor receptor superfamily member 10D","aliases":["Decoy receptor 2","DcR2","TNF-related apoptosis-inducing ligand receptor 4","TRAIL receptor 4","TRAIL-R4","TRAIL receptor with a truncated death domain"],"length_aa":386,"mass_kda":41.8,"function":"Receptor for the cytotoxic ligand TRAIL (PubMed:9430226). Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis (PubMed:9537512). Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway (PubMed:9382840, PubMed:9430226)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q9UBN6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF10D","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF10D","total_profiled":1310},"omim":[{"mim_id":"603614","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10D; TNFRSF10D","url":"https://www.omim.org/entry/603614"},{"mim_id":"603598","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 10; TNFSF10","url":"https://www.omim.org/entry/603598"},{"mim_id":"600211","title":"RUNT-RELATED TRANSCRIPTION FACTOR 2; RUNX2","url":"https://www.omim.org/entry/600211"},{"mim_id":"259500","title":"OSTEOGENIC SARCOMA","url":"https://www.omim.org/entry/259500"},{"mim_id":"190070","title":"KRAS PROTOONCOGENE, GTPase; KRAS","url":"https://www.omim.org/entry/190070"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Actin filaments","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF10D"},"hgnc":{"alias_symbol":["DcR2","TRUNDD","TRAILR4","CD264"],"prev_symbol":[]},"alphafold":{"accession":"Q9UBN6","domains":[{"cath_id":"2.10.50.10","chopping":"80-142","consensus_level":"medium","plddt":94.9503,"start":80,"end":142},{"cath_id":"-","chopping":"143-188","consensus_level":"medium","plddt":89.7707,"start":143,"end":188}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBN6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBN6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBN6-F1-predicted_aligned_error_v6.png","plddt_mean":60.97},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF10D","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF10D"},"sequence":{"accession":"Q9UBN6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UBN6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UBN6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBN6"}},"corpus_meta":[{"pmid":"9430226","id":"PMC_9430226","title":"The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430226","citation_count":700,"is_preprint":false},{"pmid":"9537512","id":"PMC_9537512","title":"TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9537512","citation_count":269,"is_preprint":false},{"pmid":"11929838","id":"PMC_11929838","title":"Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11929838","citation_count":135,"is_preprint":false},{"pmid":"10933923","id":"PMC_10933923","title":"The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.","date":"2000","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/10933923","citation_count":95,"is_preprint":false},{"pmid":"25382312","id":"PMC_25382312","title":"PARP13 regulates cellular mRNA post-transcriptionally and functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25382312","citation_count":93,"is_preprint":false},{"pmid":"17545522","id":"PMC_17545522","title":"Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17545522","citation_count":81,"is_preprint":false},{"pmid":"16230375","id":"PMC_16230375","title":"Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16230375","citation_count":71,"is_preprint":false},{"pmid":"22028813","id":"PMC_22028813","title":"Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22028813","citation_count":70,"is_preprint":false},{"pmid":"21625476","id":"PMC_21625476","title":"TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21625476","citation_count":56,"is_preprint":false},{"pmid":"15788647","id":"PMC_15788647","title":"Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15788647","citation_count":55,"is_preprint":false},{"pmid":"12838325","id":"PMC_12838325","title":"Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12838325","citation_count":54,"is_preprint":false},{"pmid":"16799475","id":"PMC_16799475","title":"Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16799475","citation_count":49,"is_preprint":false},{"pmid":"11587215","id":"PMC_11587215","title":"Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion.","date":"2001","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11587215","citation_count":45,"is_preprint":false},{"pmid":"28962588","id":"PMC_28962588","title":"Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells.","date":"2017","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28962588","citation_count":35,"is_preprint":false},{"pmid":"17853923","id":"PMC_17853923","title":"DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.","date":"2007","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17853923","citation_count":33,"is_preprint":false},{"pmid":"16990850","id":"PMC_16990850","title":"Dcr2 targets Ire1 and downregulates the unfolded protein response in Saccharomyces cerevisiae.","date":"2006","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/16990850","citation_count":27,"is_preprint":false},{"pmid":"11907838","id":"PMC_11907838","title":"Ultraviolet light (UV) regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.","date":"2001","source":"Journal of cutaneous medicine and surgery","url":"https://pubmed.ncbi.nlm.nih.gov/11907838","citation_count":26,"is_preprint":false},{"pmid":"32695113","id":"PMC_32695113","title":"Upregulated TRAIL and Reduced DcR2 Mediate Apoptosis of Decidual PMN-MDSC in Unexplained Recurrent Pregnancy Loss.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32695113","citation_count":24,"is_preprint":false},{"pmid":"28356293","id":"PMC_28356293","title":"Urinary DcR2 is a novel biomarker for tubulointerstitial injury in patients with diabetic nephropathy.","date":"2017","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28356293","citation_count":20,"is_preprint":false},{"pmid":"22136382","id":"PMC_22136382","title":"Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis.","date":"2011","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/22136382","citation_count":16,"is_preprint":false},{"pmid":"31612990","id":"PMC_31612990","title":"Survival of aging CD264+ and CD264- populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency.","date":"2019","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/31612990","citation_count":14,"is_preprint":false},{"pmid":"28461078","id":"PMC_28461078","title":"Isolation and identification of senescent renal tubular epithelial cells using immunomagnetic beads based on DcR2.","date":"2017","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/28461078","citation_count":14,"is_preprint":false},{"pmid":"19414356","id":"PMC_19414356","title":"Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.","date":"2009","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19414356","citation_count":14,"is_preprint":false},{"pmid":"19730199","id":"PMC_19730199","title":"DR5 and DcR2 are expressed in human lumbar intervertebral discs.","date":"2009","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/19730199","citation_count":12,"is_preprint":false},{"pmid":"11848467","id":"PMC_11848467","title":"Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.","date":"2001","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11848467","citation_count":11,"is_preprint":false},{"pmid":"23430714","id":"PMC_23430714","title":"Expression of TRAIL and its receptors DR5 and DcR2 in orthodontic tooth movement.","date":"2013","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23430714","citation_count":10,"is_preprint":false},{"pmid":"31487717","id":"PMC_31487717","title":"DCR2, a Cellular Senescent Molecule, Is a Novel Marker for Assessing Tubulointerstitial Fibrosis in Patients with Immunoglobulin A Nephropathy.","date":"2019","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/31487717","citation_count":10,"is_preprint":false},{"pmid":"23584885","id":"PMC_23584885","title":"Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.","date":"2013","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/23584885","citation_count":9,"is_preprint":false},{"pmid":"25003639","id":"PMC_25003639","title":"Association of TNFRSF10D DNA-methylation with the survival of melanoma patients.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25003639","citation_count":7,"is_preprint":false},{"pmid":"16245307","id":"PMC_16245307","title":"TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16245307","citation_count":7,"is_preprint":false},{"pmid":"31399243","id":"PMC_31399243","title":"Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma.","date":"2019","source":"American journal of otolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/31399243","citation_count":5,"is_preprint":false},{"pmid":"29879421","id":"PMC_29879421","title":"High-dose HOOK effect in urinary DcR2 assay in patients with chronic kidney disease.","date":"2018","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29879421","citation_count":5,"is_preprint":false},{"pmid":"29274771","id":"PMC_29274771","title":"Determination of normal expression patterns of CD86, CD210a, CD261, CD262, CD264, CD358, and CD361 in peripheral blood and bone marrow cells by flow cytometry.","date":"2017","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29274771","citation_count":5,"is_preprint":false},{"pmid":"12831538","id":"PMC_12831538","title":"Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.","date":"2003","source":"Hybridoma and hybridomics","url":"https://pubmed.ncbi.nlm.nih.gov/12831538","citation_count":5,"is_preprint":false},{"pmid":"39255671","id":"PMC_39255671","title":"TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction.","date":"2024","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/39255671","citation_count":3,"is_preprint":false},{"pmid":"33381579","id":"PMC_33381579","title":"Association of RASSF1A, DCR2, and CASP8 Methylation with Survival in Neuroblastoma: A Pooled Analysis Using Reconstructed Individual Patient Data.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/33381579","citation_count":3,"is_preprint":false},{"pmid":"25248880","id":"PMC_25248880","title":"The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.","date":"2014","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/25248880","citation_count":3,"is_preprint":false},{"pmid":"36158196","id":"PMC_36158196","title":"Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36158196","citation_count":3,"is_preprint":false},{"pmid":"40154678","id":"PMC_40154678","title":"Attenuation of cardiac ischemia/reperfusion injury via the decoy receptor DcR2 by targeting the PLAD domain of the death receptor DR5.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40154678","citation_count":2,"is_preprint":false},{"pmid":"38787503","id":"PMC_38787503","title":"ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2).","date":"2024","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/38787503","citation_count":1,"is_preprint":false},{"pmid":"16185657","id":"PMC_16185657","title":"Interferons induce proteolytic degradation of TRAILR4.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16185657","citation_count":1,"is_preprint":false},{"pmid":"40115374","id":"PMC_40115374","title":"Urinary DcR2/Cr level predicts renal outcomes in patients with diabetic kidney disease.","date":"2025","source":"Journal of clinical & translational endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/40115374","citation_count":1,"is_preprint":false},{"pmid":"24649804","id":"PMC_24649804","title":"Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.","date":"2014","source":"Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/24649804","citation_count":1,"is_preprint":false},{"pmid":"36780173","id":"PMC_36780173","title":"Knockdown of Dcr1 and Dcr2 limits the lethal effect of C-factor in Chilo suppressalis.","date":"2023","source":"Archives of insect biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36780173","citation_count":0,"is_preprint":false},{"pmid":"39980838","id":"PMC_39980838","title":"RNA sequencing identifies MAP1A and PTTG1 as predictive genes of aging CD264+ human mesenchymal stem cells at an early passage.","date":"2025","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39980838","citation_count":0,"is_preprint":false},{"pmid":"42037836","id":"PMC_42037836","title":"Epigenetic Regulation and Immune Associations of TRAIL Decoy Receptors TNFRSF10C and TNFRSF10D in Glioblastoma: A Multi-omic Analysis.","date":"2026","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/42037836","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.04.647234","title":"Enhancing Tissue-Specific Antiviral Immunity to Disrupt Arbovirus Transmission by Mosquitoes","date":"2025-04-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.04.647234","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.20.599909","title":"The PAZ domain of<i>Aedes aegypti</i>Dicer 2 is critical for accurate and high-fidelity size determination of virus-derived small interfering RNAs","date":"2024-06-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.20.599909","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26934,"output_tokens":3633,"usd":0.067649},"stage2":{"model":"claude-opus-4-6","input_tokens":7028,"output_tokens":3358,"usd":0.178635},"total_usd":0.246284,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R4 (TNFRSF10D) was cloned and characterized as a receptor that binds TRAIL, activates NF-κB similarly to TRAIL-R1/R2, but cannot induce apoptosis due to its incomplete/truncated death domain. Transient overexpression of TRAIL-R4 in TRAIL-sensitive cells confers complete protection against TRAIL-mediated killing, establishing its function as a decoy receptor that inhibits TRAIL cytotoxicity.\",\n      \"method\": \"Molecular cloning, NF-κB activation assay, transient overexpression with cell death assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original cloning paper with multiple functional assays; replicated by independent lab (PMID:9537512)\",\n      \"pmids\": [\"9430226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TRUNDD (TRAIL-R4/TNFRSF10D) has an extracellular TRAIL-binding domain but lacks a functional intracellular death domain; ectopic expression of TRUNDD attenuates TRAIL-induced apoptosis in mammalian cells, confirming its role as an inhibitory decoy receptor.\",\n      \"method\": \"Molecular cloning, transient overexpression, cell death assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — independent replication of decoy function with direct overexpression/apoptosis assay\",\n      \"pmids\": [\"9537512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TRUNDD (DcR2/TRAIL-R4) expression is induced by p53 (via adenovirus-p53 overexpression), and overexpression of TRUNDD delays killing by TRAIL, p53, or KILLER/DR5. Protection against TRAIL did not require an intact intracellular domain (ICD), but the first 43 amino acids of the ICD were required for protection against p53- or KILLER/DR5-induced cell death, revealing distinct structural requirements for different protective functions.\",\n      \"method\": \"Adenoviral p53 overexpression, TRUNDD overexpression, deletion mutagenesis, co-transfection cell death assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis dissecting ICD requirements combined with functional cell death assays\",\n      \"pmids\": [\"10933923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DcR2 (TNFRSF10D) is a direct p53 target gene: a p53-binding site (p53BS) was identified in the first intron of DcR2, p53 protein binds to this site in intact cells (chromatin immunoprecipitation), and the p53BS is sufficient to drive transcriptional activation by wild-type p53. Overexpression of DcR2 conferred resistance to TRAIL-mediated apoptosis and attenuated chemotherapeutic agent-induced apoptosis, while DcR2 silencing enhanced chemotherapy-induced apoptosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay with p53BS, siRNA knockdown, cell death assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus reporter assay plus mutagenesis of binding site plus functional KD/OE\",\n      \"pmids\": [\"16230375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Upon TRAIL binding, TRAIL-R4 forms a heteromeric complex with the agonistic receptor TRAIL-R2, leading to reduced caspase-8 activation and apoptosis. Additionally, in a ligand-independent manner, TRAIL-R4 signals through AKT/PI3K in HeLa cells, inducing morphological changes, enhanced proliferation in vitro, and tumor growth in vivo; disruption of PI3K/AKT with LY294002, p85 siRNA, or PTEN overexpression partially restored TRAIL-mediated apoptosis.\",\n      \"method\": \"Ectopic TRAIL-R4 expression, caspase-8 activation assay, PI3K/AKT inhibition (LY294002, siRNA, PTEN overexpression), in vivo xenograft tumor growth assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pharmacological, genetic, in vivo) with functional readouts; establishes heteromeric complex and AKT signaling\",\n      \"pmids\": [\"21625476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Acquisition of DcR2 (TRAIL-R4) surface expression by BTK-143 osteosarcoma cells during serial passaging correlates with progressive resistance to TRAIL-induced apoptosis; blocking DcR2 function with a specific anti-DcR2 antibody restored TRAIL sensitivity in a dose-dependent manner, directly implicating DcR2 surface expression in TRAIL resistance.\",\n      \"method\": \"Flow cytometry, anti-DcR2 antibody blocking, apoptosis assay\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blocking with dose-dependent restoration of apoptosis; single lab\",\n      \"pmids\": [\"12838325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IFNγ and IFNα strongly inhibit TRAIL-R4 cell surface expression through proteasome-dependent proteolytic degradation (blocked by MG132 and a protease inhibitor cocktail), while having moderate or inducing effects on TRAIL-R2. siRNA-mediated inhibition of TRAIL-R4 expression sensitizes cells to TRAIL- but not CD95L-induced apoptosis.\",\n      \"method\": \"Flow cytometry, proteasome inhibitor (MG132), protease inhibitor cocktail, siRNA knockdown, apoptosis assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with proteasome inhibitors and siRNA; single lab\",\n      \"pmids\": [\"16185657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Testosterone specifically controls DcR2 (TNFRSF10D) expression in the adult rat ventral prostate. Androgen deprivation (castration) reduces DcR2 mRNA and protein levels, and testosterone replacement prevents this decrease; the anti-androgen flutamide also specifically decreases DcR2 expression. No changes in DR4, DR5, DcR1, or TRAIL were observed, establishing DcR2 as an androgen-regulated gene in prostate.\",\n      \"method\": \"Castration model, testosterone replacement, flutamide treatment, RT-PCR, Western blot\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal in vivo experiments (castration + hormone replacement + antagonist) with mRNA and protein readouts; single lab\",\n      \"pmids\": [\"16245307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PARP13 (ZAP/ZC3HAV1) binds to the 3' UTR of TRAILR4 (TNFRSF10D) mRNA and destabilizes it in an exosome-dependent manner, post-transcriptionally repressing TRAILR4 expression. Knockdown of PARP13 leads to upregulation of TRAILR4 transcript and reduced cell sensitivity to TRAIL-mediated apoptosis, establishing PARP13 as a regulator of the cellular TRAIL response via TRAILR4 mRNA decay.\",\n      \"method\": \"PARP13 knockdown (siRNA), RNA-seq, RNA immunoprecipitation, exosome-dependent mRNA decay assay, TRAIL apoptosis assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (RIP, exosome inhibition, KD with functional readout) in single rigorous study\",\n      \"pmids\": [\"25382312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Stable knockdown of endogenous TRAIL-R4 in Colo357 and MDA-MB-231 cancer cells reveals context-dependent signaling: in Colo357 cells, TRAIL-R4 KD strongly increased apoptosis and reduced clonogenic survival; in MDA-MB-231 cells, TRAIL-R4 KD paradoxically inhibited cell death and improved survival by upregulating Bcl-xL (Navitoclax restored apoptosis). TRAIL-R4 KD also reduced FLIPs, XIAP, and cIAP2 levels in MDA-MB-231. In both lines, TRAIL-R4 KD constitutively increased AKT and ERK activity, and potentiated TRAIL-induced NF-κB and MAPK signaling.\",\n      \"method\": \"Stable shRNA knockdown, clonogenic survival assay, Western blot (caspase-8, FLIPs, XIAP, cIAP2, Bcl-xL), Navitoclax inhibition, AKT/ERK/p38/NF-κB pathway activation assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — stable KD with multiple pathway readouts and rescue experiment (Navitoclax); mechanistically rigorous\",\n      \"pmids\": [\"36158196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DcR2 (TNFRSF10D) has greater binding affinity for DR5 than for TRAIL itself. DcR2 forms a heterocomplex with DR5 through its PLAD (pre-ligand assembly domain), and deletion of PLAD eliminates the cardioprotective effect of an hDcR2-Fc fusion protein in a mouse model of myocardial ischemia/reperfusion injury. This establishes DcR2 as a ligand for DR5 that blocks apoptosis by DR5 heterocomplex formation via PLAD, independent of TRAIL binding.\",\n      \"method\": \"Affinity binding assay (DcR2 vs. TRAIL and DR5), PLAD deletion mutagenesis, hDcR2-Fc fusion protein, mouse myocardial I/R injury model, apoptosis assay\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — affinity assay plus domain mutagenesis plus in vivo functional model; multiple orthogonal methods\",\n      \"pmids\": [\"40154678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The transcription factor ELF3 regulates TRAIL sensitivity in breast cancer cells by modulating DcR2 (TNFRSF10D) expression; ELF3 overexpression in MDA-MB-231 and MCF7 cells reverses TRAIL resistance and simultaneously downregulates DcR2 protein levels.\",\n      \"method\": \"ELF3 overexpression, cell viability assay, cleaved caspase-3 immunoblotting, DcR2 immunoblotting\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — overexpression with functional readout linking ELF3→DcR2→TRAIL sensitivity; single lab, no ChIP or direct promoter assay\",\n      \"pmids\": [\"38787503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Tumor-specific down-regulation of DcR2 (TNFRSF10D) in neuroblastoma and other tumor cell lines is associated with dense CpG island hypermethylation of the DcR2 promoter; treatment with the demethylating agent 5-aza-2'-deoxycytidine results in partial demethylation and restored DcR2 mRNA expression, establishing epigenetic silencing as a mechanism of DcR2 loss.\",\n      \"method\": \"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine demethylation, RT-PCR\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological demethylation restores expression; single lab but orthogonal methylation and expression methods\",\n      \"pmids\": [\"11929838\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF10D (TRAIL-R4/DcR2) is a decoy receptor that binds TRAIL but cannot induce apoptosis due to its truncated death domain; it inhibits TRAIL-induced apoptosis by competing with death receptors and by forming heteromeric complexes with TRAIL-R2/DR5 via its PLAD domain, while also activating NF-κB and PI3K/AKT pro-survival signaling; its expression is transcriptionally regulated by p53 and androgens, post-transcriptionally repressed by PARP13-mediated mRNA decay, and epigenetically silenced by promoter hypermethylation in tumors, with interferon-induced proteasomal degradation providing an additional layer of regulation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFRSF10D (TRAIL-R4/DcR2) is a decoy receptor in the TRAIL death receptor pathway that antagonizes apoptosis through multiple mechanisms while simultaneously activating pro-survival signaling. It binds TRAIL via its extracellular domain but cannot transduce apoptotic signals due to a truncated intracellular death domain; instead, it inhibits apoptosis by competing with death receptors for TRAIL and by forming heteromeric complexes with TRAIL-R2/DR5 through its pre-ligand assembly domain (PLAD), with DcR2 exhibiting greater binding affinity for DR5 than for TRAIL itself [PMID:9430226, PMID:40154678]. In a ligand-independent manner, TNFRSF10D activates NF-κB, AKT/PI3K, and ERK signaling to promote cell survival and proliferation, though stable knockdown reveals context-dependent effects whereby loss of DcR2 can paradoxically inhibit apoptosis in certain cell lines through compensatory Bcl-xL upregulation [PMID:21625476, PMID:36158196]. Its expression is transcriptionally controlled by p53 (via an intronic p53-binding site) and androgens, post-transcriptionally repressed by PARP13-mediated mRNA decay, epigenetically silenced by promoter CpG hypermethylation in tumors, and regulated at the protein level by interferon-induced proteasomal degradation [PMID:16230375, PMID:16245307, PMID:25382312, PMID:11929838, PMID:16185657].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The cloning of TRAIL-R4/DcR2 resolved how cells could bind TRAIL yet resist apoptosis, revealing a receptor that activates NF-κB but has a truncated death domain incapable of death signaling, thereby establishing the concept of a decoy receptor in the TRAIL system.\",\n      \"evidence\": \"Molecular cloning, NF-κB reporter assays, and transient overexpression protection against TRAIL-mediated killing; independently replicated\",\n      \"pmids\": [\"9430226\", \"9537512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which DcR2 blocks signaling at death receptors was unknown beyond simple competition for ligand\",\n        \"Physiological expression patterns and transcriptional regulation uncharacterized\",\n        \"Whether DcR2 transmits any active survival signals beyond NF-κB was unknown\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Deletion mutagenesis of DcR2's intracellular domain distinguished two protective mechanisms: the extracellular domain sufficed to block TRAIL, but the first 43 amino acids of the ICD were specifically required for protection against p53- or KILLER/DR5-induced cell death, revealing that DcR2 is not simply a passive ligand sink.\",\n      \"evidence\": \"ICD deletion constructs co-expressed with p53 or KILLER/DR5, functional cell death assays\",\n      \"pmids\": [\"10933923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The signaling mechanism mediated by the proximal ICD fragment was not identified\",\n        \"Whether DcR2 physically interacts with DR5 was not tested\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The finding that DcR2 promoter hypermethylation silences its expression in neuroblastoma and other tumors, reversible by demethylating agents, explained how tumors can lose a decoy receptor and provided an epigenetic mechanism for altered TRAIL pathway sensitivity in cancer.\",\n      \"evidence\": \"Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment restoring mRNA\",\n      \"pmids\": [\"11929838\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequences of demethylation on TRAIL-induced apoptosis were not directly tested\",\n        \"Single-lab observation at this time; breadth across tumor types was limited\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Anti-DcR2 antibody blocking in osteosarcoma cells that had acquired DcR2 surface expression during passaging restored TRAIL sensitivity dose-dependently, providing the first loss-of-function evidence that endogenous DcR2 at the cell surface is a physiologically relevant barrier to TRAIL-induced apoptosis.\",\n      \"evidence\": \"Flow cytometry for DcR2 surface expression, anti-DcR2 blocking antibody, apoptosis assays\",\n      \"pmids\": [\"12838325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism of DcR2 upregulation during passaging was not determined\",\n        \"Antibody blocking does not distinguish competition for TRAIL from disruption of receptor–receptor complexes\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of a direct p53-binding site in DcR2's first intron by ChIP and reporter assays established DcR2 as a bona fide p53 target gene, revealing a negative feedback loop in which p53-induced apoptosis is modulated by p53-driven expression of an anti-apoptotic decoy receptor.\",\n      \"evidence\": \"ChIP, luciferase reporter with p53BS, p53BS mutagenesis, siRNA knockdown with chemotherapy apoptosis assay\",\n      \"pmids\": [\"16230375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether p53-mediated DcR2 induction occurs in non-tumor physiological contexts was not shown\",\n        \"Relative contribution of p53-driven DcR2 vs. other p53 targets in modulating apoptotic outcome was unclear\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that interferons (IFNγ, IFNα) reduce DcR2 surface expression via proteasome-dependent degradation revealed a protein-level regulatory mechanism that sensitizes cells to TRAIL, complementing the known transcriptional and epigenetic controls.\",\n      \"evidence\": \"Flow cytometry, proteasome inhibitor MG132 rescue, siRNA-mediated DcR2 knockdown, TRAIL apoptosis assay\",\n      \"pmids\": [\"16185657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The E3 ubiquitin ligase responsible for DcR2 ubiquitylation was not identified\",\n        \"Whether interferon-induced degradation operates in vivo was not tested\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The finding that testosterone specifically maintains DcR2 expression in rat prostate (while other TRAIL receptors are unaffected) identified DcR2 as an androgen-regulated gene, providing a mechanism by which androgen deprivation therapy could sensitize prostate tissue to TRAIL-mediated apoptosis.\",\n      \"evidence\": \"Castration, testosterone replacement, flutamide treatment; RT-PCR and Western blot in rat ventral prostate\",\n      \"pmids\": [\"16245307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether androgen receptor directly binds the DcR2 promoter was not tested\",\n        \"Functional link between androgen-regulated DcR2 and TRAIL sensitivity in prostate was not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The discovery that TRAIL-R4 forms a heteromeric complex with TRAIL-R2 to reduce caspase-8 activation, and independently activates AKT/PI3K signaling to promote proliferation and tumor growth, established DcR2 as both a dominant-negative receptor and an active oncogenic signaling molecule.\",\n      \"evidence\": \"Ectopic TRAIL-R4 expression, caspase-8 assay, PI3K inhibition (LY294002, p85 siRNA, PTEN OE), xenograft model\",\n      \"pmids\": [\"21625476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The molecular mechanism linking DcR2's truncated death domain to PI3K/AKT activation was not resolved\",\n        \"The stoichiometry and structural basis of the TRAIL-R4/TRAIL-R2 heterocomplex were not determined\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of PARP13 as a post-transcriptional repressor that binds the TRAILR4 3′ UTR and triggers exosome-dependent mRNA decay added an RNA regulatory layer to DcR2 control, explaining how cells can fine-tune TRAIL sensitivity independently of transcription.\",\n      \"evidence\": \"PARP13 siRNA knockdown, RNA-seq, RNA immunoprecipitation, exosome inhibition, TRAIL apoptosis assay\",\n      \"pmids\": [\"25382312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific RNA sequences/structures in the 3′ UTR recognized by PARP13 were not mapped\",\n        \"Whether PARP13-mediated DcR2 repression operates in non-cancer contexts was not explored\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Stable DcR2 knockdown in two cancer cell lines revealed that DcR2's role is context-dependent: pro-survival in one line (Colo357) but paradoxically pro-apoptotic in another (MDA-MB-231) via compensatory Bcl-xL upregulation, challenging a simple decoy receptor model and showing that DcR2 actively shapes the signaling landscape through NF-κB, AKT, and ERK pathways.\",\n      \"evidence\": \"Stable shRNA KD in Colo357 and MDA-MB-231, clonogenic assays, pathway Western blots, Navitoclax rescue of Bcl-xL-dependent survival\",\n      \"pmids\": [\"36158196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which DcR2 loss leads to Bcl-xL upregulation in MDA-MB-231 was not delineated\",\n        \"Which downstream effectors mediate the context-dependent switch was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that DcR2 binds DR5 with higher affinity than TRAIL and that its PLAD domain is required for heterocomplex formation and cardioprotection in myocardial ischemia/reperfusion injury redefined DcR2 as a direct DR5 ligand/modulator acting through receptor–receptor interactions rather than solely through ligand sequestration.\",\n      \"evidence\": \"Affinity binding assays, PLAD deletion mutagenesis, hDcR2-Fc fusion protein, mouse myocardial I/R model\",\n      \"pmids\": [\"40154678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the PLAD-mediated DcR2–DR5 interaction at atomic resolution is unknown\",\n        \"Whether PLAD-dependent DR5 inhibition operates in tissues beyond the heart was not tested\",\n        \"Relative contribution of TRAIL sequestration vs. DR5 heterocomplexing in physiological settings remains unquantified\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of DcR2–DR5 PLAD interaction, the signaling intermediates linking DcR2's truncated death domain to PI3K/AKT activation, and the molecular determinants that dictate context-dependent pro-survival versus pro-apoptotic outcomes upon DcR2 loss.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of the DcR2–DR5 heterocomplex exists\",\n        \"The adaptor proteins linking DcR2 to PI3K/AKT have not been identified\",\n        \"In vivo genetic knockout models for DcR2 have not been reported\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 4, 10]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 9, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF10\",\n      \"TNFRSF10B\",\n      \"ZC3HAV1\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}